Methicillin-resistant staphylococcus aureus infectious disease
disease diseaseOn this page
Also known as MRSA
Summary
Methicillin-resistant staphylococcus aureus infectious disease (MONDO:0100073) is a disease and 21 clinical trials. Top therapeutic interventions include cephalexin anhydrous, clindamycin, and doxycycline anhydrous. A subtype of staphylococcus aureus infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | methicillin-resistant staphylococcus aureus infectious disease |
| Mondo ID | MONDO:0100073 |
| EFO | EFO:0008555 |
| UMLS | C0343401 |
| MedGen | 575565 |
| Is cancer (heuristic) | no |
Also known as: MRSA
Disease family
This is a subtype of staphylococcus aureus infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › staphylococcal infection › staphylococcus aureus infection › methicillin-resistant staphylococcus aureus infectious disease
Related subtypes (6): impetigo, hordeolum, staphylococcal scalded skin syndrome, staphylococcus aureus pneumonia, methicillin-susceptible staphylococcus aureus infectious disease, staphylococcus discitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE4 | 6 |
| PHASE3 | 3 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04297592 | PHASE4 | ENROLLING_BY_INVITATION | Antibiotic Prophylaxis in High-Risk Arthroplasty Patients |
| NCT01167452 | PHASE4 | COMPLETED | Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations |
| NCT02029872 | PHASE4 | COMPLETED | Stop Community MRSA Colonization Among Patients |
| NCT02127658 | PHASE4 | TERMINATED | MRSA Eradication and Decolonization in Children |
| NCT02443064 | PHASE4 | UNKNOWN | Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin |
| NCT02547116 | PHASE4 | WITHDRAWN | Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis |
| NCT03181932 | PHASE3 | COMPLETED | AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis |
| NCT03304873 | PHASE3 | COMPLETED | Retapamulin as a Decolonizing Agent for MRSA |
| NCT04104178 | PHASE3 | COMPLETED | Optimal Treatment of MRSA Throat Carriers |
| NCT05696132 | PHASE2 | TERMINATED | Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients |
| NCT04793152 | Not specified | RECRUITING | Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC |
| NCT05268120 | Not specified | RECRUITING | MRSA Decolonization in Complicated Carriage |
| NCT00822276 | Not specified | COMPLETED | The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) |
| NCT01318213 | Not specified | COMPLETED | Benefits of Universal Glove and Gowning |
| NCT02652325 | Not specified | UNKNOWN | Nasal Swab studyComparison of Effectiveness of Povidone-iodine Versus Saline Versus 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP Swabs for Decolonizing Intranasal MSSA/MRSA |
| NCT02690415 | Not specified | COMPLETED | Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses |
| NCT03268122 | Not specified | COMPLETED | Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE |
| NCT03601741 | Not specified | COMPLETED | Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination |
| NCT04083092 | Not specified | UNKNOWN | Surveillance of Community-Associated MRSA |
| NCT04312776 | Not specified | COMPLETED | Tracing MRSA in Households With Patients Infected With CA-MRSA by WGS |
| NCT05395520 | Not specified | UNKNOWN | Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections? |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CEPHALEXIN ANHYDROUS | 4 | 3 |
| CLINDAMYCIN | 4 | 3 |
| DOXYCYCLINE ANHYDROUS | 4 | 3 |
| MUPIROCIN | 4 | 2 |
| POVIDONE-IODINE | 4 | 2 |
| VANCOMYCIN | 4 | 2 |
| CEFADROXIL | 4 | 1 |
| RETAPAMULIN | 4 | 1 |
| RIFAMPIN | 4 | 1 |
| SODIUM HYPOCHLORITE | 4 | 1 |
| SULFAMETHOXAZOLE | 4 | 1 |
| TRIMETHOPRIM | 4 | 1 |
| CHEMBL4793658 | 0 | 2 |
| CHEMBL4299436 | 0 | 1 |
| CHEMBL1555813 | 0 | 1 |
| CHEMBL4755088 | 0 | 1 |
| CHEMBL5282170 | 0 | 1 |